Business
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
Initiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":" Initiating three clinical studies in chronic cough indications later this year\nReceived Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in idiopathic pulmonary fibrosis\nManagement to host a conference call and webcast today at 4:30 p.m. EDT\nNEW HAVEN, Conn., May 11, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications and prurigo nodularis (PN), today announced financial results for the quarter ended March 31, 2023, as well as provided business updates.\n\n \n \n \n \n \n \n\n \n\"We have been focused on progressing our clinical development plans as we work to initiate clinical trials in both chronic cough in IPF and in refractory chronic cough as well as advance our human abuse potential study,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"Our efforts remain on track with the completion of the open-label extension trial for PN and part 1 of the human abuse potential study in the first quarter, as well as advancing key activities to initiate the trials in each of the chronic cough indications in the second half of this year.\" \nKey Business Updates\nChronic cough trials:Phase 2b dose ranging trial for the treatment of chronic cough in IPF is expected to initiate in the second half of 2023.Phase 1b trial to evaluate the effect on respiratory physiology in IPF patients is expected to initiate in the second half of 2023.Phase 2a trial in refractory chronic cough is expected to initiate in the third quarter of 2023.Completed part 1 of the human abuse potential study characterizing butorphanol and selected a butorphanol dose for part 2.Received Notice of Allowance for U.S. patent application covering the use of nalbuphine ER for the treatment of chronic cough in IPF. Trevi expects the resulting patent will be eligible for listing in the Orange Book with an anticipated expiration in 2039.Completed the open-label extension portion of the Phase 2b/3 PRISM trial for the treatment of prurigo nodularis during the first quarter of 2023. Data from the extension study is being analyzed and the Company will request an En...